Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?

[1]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[2]  M. Domanski,et al.  Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the &bgr;-Blocker Evaluation of Survival Trial , 2004, Circulation.

[3]  Stephanie Läer,et al.  Carvedilol but Not Metoprolol Reduces β-Adrenergic Responsiveness After Complete Elimination From Plasma In Vivo , 2004, Circulation.

[4]  P. Poole‐Wilson.  Commentary on the Carvedilol or Metoprolol European Trial (COMET). , 2004, The American journal of cardiology.

[5]  M. Metra,et al.  835-2 Carvedilol better protects against vascular events than metoprolol in heart failure: Results from COMET , 2004 .

[6]  P. Poole‐Wilson,et al.  1012-121 Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: Results from the carvedilol or metoprolol European trial (COMET) , 2004 .

[7]  M. Metra,et al.  Current guidelines in the pharmacological management of chronic heart failure , 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[8]  J. Herlitz,et al.  Similar Risk Reduction of Death of Extended-Release Metoprolol Once Daily and Immediate-Release Metoprolol Twice Daily During 5 Years After Myocardial Infarction , 1999, Cardiovascular Drugs and Therapy.

[9]  M. Gheorghiade,et al.  Carvedilol: beta-blockade and beyond. , 2004, Reviews in cardiovascular medicine.

[10]  P. Lundborg,et al.  Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets , 2004, European Journal of Clinical Pharmacology.

[11]  M. Packer.  Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial , 2003 .

[12]  K. Adams,et al.  Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? , 2003, Journal of cardiac failure.

[13]  B. Massie.  A comment on COMET: how to interpret a positive trial? , 2003, Journal of cardiac failure.

[14]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[15]  M. Domanski,et al.  A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. , 2003, Journal of cardiac failure.

[16]  E. Lakatta,et al.  Enhanced Gi Signaling Selectively Negates &bgr;2-Adrenergic Receptor (AR)– but Not &bgr;1-AR–Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts , 2003, Circulation.

[17]  F. Waagstein,et al.  COMET: a proposed mechanism of action to explain the results and concerns about dose , 2003, The Lancet.

[18]  H. Schäfers,et al.  Partial Agonist Activity of Bucindolol Is Dependent on the Activation State of the Human &bgr;1‐Adrenergic Receptor , 2003, Circulation.

[19]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[20]  H. Dargie.  β blockers in heart failure , 2003, The Lancet.

[21]  M. Bristow.  Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. , 2003, Circulation.

[22]  J. Rouleau,et al.  Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. , 2003, JAMA.

[23]  M. Packer.  Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial. , 2003, Journal of cardiac failure.

[24]  M. Metra,et al.  Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. , 2002, Journal of the American College of Cardiology.

[25]  P. Poole‐Wilson,et al.  Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET , 2002, European journal of heart failure.

[26]  W. Koch,et al.  Specific β2AR Blocker ICI 118,551 Actively Decreases Contraction Through a Gi-Coupled Form of the β2AR in Myocytes From Failing Human Heart , 2002 .

[27]  N. Aiyar,et al.  Bucindolol Displays Intrinsic Sympathomimetic Activity in Human Myocardium , 2002, Circulation.

[28]  K. Swedberg,et al.  Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure , 2002, Circulation.

[29]  K. Swedberg,et al.  Comprehensive guidelines for the diagnosis and treatment of chronic heart failure Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology , 2002, European journal of heart failure.

[30]  D. Sawyer,et al.  Adrenergic regulation of cardiac myocyte apoptosis , 2001, Journal of cellular physiology.

[31]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[32]  T. Yoshikawa,et al.  Bucindolol, a Nonselective &bgr;1‐ and &bgr;2‐Adrenergic Receptor Antagonist, Decreases &bgr;‐Adrenergic Receptor Density in Cultured Embryonic Chick Cardiac Myocyte Membranes , 2001, Journal of cardiovascular pharmacology.

[33]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[34]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[35]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[36]  C. Yancy,et al.  Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. , 2001, The New England journal of medicine.

[37]  Klaus-DieterSchlüter.  β2-Adrenergic Receptor Overexpression Exacerbates Development of Heart Failure After Aortic Stenosis , 2001 .

[38]  M. Metra,et al.  β-Blockade in Heart Failure , 2001 .

[39]  M. Metra,et al.  Beta-blockade in heart failure: selective versus nonselective agents. , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[40]  John Wikstrand,et al.  Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients with Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) , 2000 .

[41]  N. Freemantle,et al.  Are beta‐blockers effective in patients who develop heart failure soon after myocardial infarction? A meta‐regression analysis of randomised trials , 2000, European journal of heart failure.

[42]  M. Metra,et al.  Differential Effects of β-Blockers in Patients With Heart Failure , 2000 .

[43]  M. Metra,et al.  A rationale for the use of β-blockers as standard treatment for heart failure , 2000 .

[44]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[45]  R. McKelvie,et al.  Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. , 2000, Circulation.

[46]  M. Bristow.  beta-adrenergic receptor blockade in chronic heart failure. , 2000, Circulation.

[47]  ICHAEL,et al.  THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE , 2000 .

[48]  M. Metra,et al.  A rationale for the use of beta-blockers as standard treatment for heart failure. , 2000, American heart journal.

[49]  M. Kukin,et al.  Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. , 2000, Journal of the American College of Cardiology.

[50]  M. Metra,et al.  Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. , 2000, Circulation.

[51]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[52]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[53]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[54]  M. Packer.  Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. , 1998, Progress in cardiovascular diseases.

[55]  M. Bristow.  Mechanism of action of beta-blocking agents in heart failure. , 1997, The American journal of cardiology.

[56]  M. Kukin,et al.  β Blockade in congestive heart failure: persistent adverse haemodynamic effects during chronic treatment with subsequent doses , 1997, Heart.

[57]  G. Billman,et al.  Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. , 1997, Circulation.

[58]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[59]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[60]  G. Newton,et al.  Acute Effects of β1-Selective and Nonselective β-Adrenergic Receptor Blockade on Cardiac Sympathetic Activity in Congestive Heart Failure , 1996 .

[61]  G. Newton,et al.  Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. , 1996, Circulation.

[62]  M. Brown.  Beta-blockers in heart failure. , 1994, Lancet.

[63]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[64]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[65]  H. Ikram,et al.  Xamoterol in severe heart failure , 1990, The Lancet.

[66]  M. Brown,et al.  Selective j31-Adrenoceptor Blockade Enhances Positive Inotropic Responses toEndogenous Catecholamines Mediated Through j2-Adrenoceptors inHumanAtrial Myocardium , 1990 .

[67]  M. Petch,et al.  Intracoronary Injections of Salbutamol Demonstrate the Presence of Functional ft-Adrenoceptors in the Human Heart , 1989, Circulation research.

[68]  R. Byington,et al.  Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.

[69]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[70]  The effect of pindolol on the two years mortality after complicated myocardial infarction. , 1983, European heart journal.

[71]  J. Kjekshus,et al.  Timolol‐related Reduction in Mortality and Reinfarction in Patients Ages 65‐75 Years Surviving Acute Myocardial Infarction , 1982, Circulation.